# Veeva Systems Inc. (VEEV) — InvestMoat Analysis

_Last analyzed: September 17, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/veev_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 81 |
| Growth trajectory | 78 |
| Valuation | 74 |
| **Composite** | **79** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** VEEV
- **Market Cap:** ~$44B

## Moat

Veeva's moat is switching-cost system-of-record lock-in inside life sciences: Vault content (clinical, regulatory, quality, safety) plus Commercial Cloud CRM are validated into GxP workflows where ripping them out means re-qualification, process risk, and field disruption. Competitors (IQVIA, horizontal CRM, point solutions) can sell a module; replacing an installed Vault + CRM stack is operationally and regulatorily painful.

### The Life-Sciences Industry-Cloud SoR Moat

VEEV runs a **Mission-Critical Industry Cloud Toll** that compounds through validated SoR embedding, suite breadth, and an emerging agent layer:

- **Vault as Regulated System of Record:** Development Cloud and Quality Cloud sit inside clinical, regulatory, quality, and safety document and process workflows that customers validate under GxP / 21 CFR Part 11-style controls. Q2 added 30+ Development Cloud customers and 30+ Quality customers; Safety surpassed 100 customers with a second top-20 Safety Workbench win. Once Vault holds the authoritative content trail, switching is a multi-year revalidation project — classic SoR + transaction embedding, not a seat that IT swaps overnight.
- **Vault CRM / Commercial Switching Costs:** Commercial Solutions subscription printed $347.4M (+13% YoY). Management called Q2 the best CRM quarter ever: >180 Vault CRM customers live (five top-20 biopharmas), 12 top-20 commitments globally, and a top-20 U.S. field go-live with Agentic Call Report. Migrations off Salesforce-era life-sciences CRM and SMB wins reinforce that the commercial field force is standardizing on Vault CRM — high switching cost once call reports, content, and compliance sit in one stack.
- **Suite Bundle (Commercial + R&D + Data):** R&D and Quality Solutions subscription $419.4M (+19% YoY) now outgrows Commercial and is the larger subscription engine. Crossix, Compass/Link/OpenData, Ostro, and services deepen the account. Bundling raises the cost of cherry-picking IQVIA or a horizontal CRM for one workflow. Thin first pass does not underwrite NRR or attach rates product-by-product — flagged for restamp.
- **AI / Falcon Layer (Open Depth):** Vault AI agents, Falcon (agentic labor for clinical/regulatory/safety; five early adopters), Falcon MLR (Copli), and Aspen CRM (horizontal AI CRM) are the next chapter. AI can deepen the SoR rather than displace it if agents stay tied to Vault data and validated workflows — but Falcon revenue, Aspen durability, and win rates vs IQVIA/Salesforce-adjacent stacks are not underwritten on this thin pass.

**Moat verdict:** VEEV's moat is AI-resilient regulated SoR embedding: Vault content + Commercial CRM inside validated life-sciences workflows. Agents (Falcon, Vault AI) can deepen the toll if they stay tied to Vault data; they do not painlessly relocate a validated stack. Falcon/Aspen and Data Cloud are additive but not yet fully underwritten fortresses on this thin first pass.

## Growth

Q2 FY2027 (reported Aug 26, 2026; quarter ended Jul 31) printed total revenue $928.0M (+18%), subscription $766.8M (+16%), professional services $161.2M (+24%). Segment subscription: Commercial Solutions $347.4M (+13%), R&D and Quality Solutions $419.4M (+19%). Non-GAAP operating income $415.9M (+18%, ~44.8% margin); non-GAAP diluted EPS $2.35 (+18%); GAAP operating income $275.0M (+40%); GAAP diluted EPS $1.66. Normalized billings $768M (+19%). Management raised FY2027 total revenue to $3.682–$3.687B (~15% YoY), subscription to ~$3.080B (~15%; Commercial ~$1.405B, R&D/Quality ~$1.675B), services $602–$607M, non-GAAP OI ~$1.640B (~44% margin), non-GAAP EPS ~$9.21 on ~165M diluted shares. Q3 guide: total rev $932–$935M, subscription ~$782M (~15%), non-GAAP EPS $2.33–$2.34. Cash + short-term investments ~$7.2B; deferred revenue $1.31B; long-duration RPO beyond deferred revenue disclosed as not significant.

- **Revenue CAGR estimate:** 14-18%
- **Primary type:** both
- **Margin trend:** stable
- **Key risk (moderate):** If subscription growth decelerates below ~12% for two consecutive quarters — because Vault CRM top-20 conversion stalls, R&D/Quality mix fades, or biopharma IT budgets cut — the 14–18% CAGR band has to be rewritten lower before any hire talk.
- **Drivers:**
  - R&D and Quality subscription — Q2 $419.4M (+19% YoY); FY2027 guide ~$1.675B; Development Cloud / Quality / Safety customer adds (accelerating)
  - Commercial / Vault CRM — Q2 Commercial sub $347.4M (+13%); >180 Vault CRM live, 12 top-20 commitments; best CRM quarter framing (accelerating)
  - Services + Data Cloud — Services Q2 $161M (+24%); FY services $602–$607M; Data Cloud +14 customers / 8 Compass brand wins — steady, not yet a second fortress (stable)
- **Score derivation:** Base 80.7 (14–18% CAGR midpoint 16%; 70+((16−8)/7)×10) + 2.7 trajectory (R&D/Quality and CRM momentum accelerating; Data Cloud stable) + 0 stable elite margins (~44–45% non-GAAP OI) − 5 moderate risk (top-20 CRM conversion / IQVIA-Salesforce competition / biopharma budget cyclicality) = 78

## Valuation

At $263.75 (Yahoo Sep 17, 2026 live), VEEV screens about 46% above the $180 bear and about 18% below the $320 base. On FY2027 non-GAAP EPS guide (~$9.21) the stock is ~28.6× FY2027E earnings and ~11.8× FY2027E sales (~$3.685B mid) — a quality vertical-software multiple that is fair if mid-teens subscription holds, rich if growth reverts to low-double digits without Falcon proof. Thin first pass — ladder is EPS-multiple anchored, not a full DCF/FCF build.

**Fair value:** $320 — Base fair value $320 assumes subscription sustains mid-teens into FY2028, non-GAAP OI margins hold ~44%+, Vault CRM finishes top-20 conversion, and the market pays ~30–32× on ~$10–11 look-through non-GAAP EPS. Live tape $263.75 (Sep 17); ~$44B equity value on ~165M diluted shares (guide). Not a hire screen — coverage valuation only.

| Multiple | Value | Note |
| --- | --- | --- |
| Price / FY2027E Non-GAAP EPS | ~28.6× | $263.75 ÷ ~$9.21 FY2027 non-GAAP EPS guide |
| Price / FY2027E Sales | ~11.8× | ~$44B equity / ~$3.685B midpoint of $3.682–$3.687B total-revenue guide |
| Non-GAAP operating margin (Q2 / FY guide) | ~44.8% / ~44% | Q2 non-GAAP OI $415.9M; FY non-GAAP OI guide ~$1.640B |
| Subscription mix (Q2) | ~83% | $766.8M subscription / $928.0M total; FY sub guide ~$3.080B |
| Balance-sheet snapshot (Jul 31) | Cash+STI ~$7.2B / essentially no debt | Deferred revenue $1.31B; ~$1.4B buyback authorization remaining; long-term RPO beyond deferred revenue not significant per 10-Q |

VEEV is priced as a durable mid-teens life-sciences software compounder, not as a distressed SaaS name and not as a hypergrowth 40×+ nostalgia print. If FY2027 lands near $9.21 non-GAAP EPS and subscription holds ~15%, ~29× leaves modest upside toward the $320 base. If subscription fades toward ~10% and Falcon/Aspen stay science projects, the multiple can compress toward the $180 bear without a balance-sheet accident. NRR, Falcon ARR, and remaining top-20 CRM decisions remain the largest unmodeled swings on this thin pass. _(as of September 17, 2026)_

## Price scenarios

### Bear — $180

Subscription decelerates to high-single / low-double digits, Vault CRM top-20 stalls, and the quality multiple compresses toward ~22× on flattish EPS.

- Subscription growth falls below ~12% for two+ quarters as biopharma budgets tighten or Vault CRM conversions slip
- Remaining top-20 CRM decisions go to IQVIA / other stacks; win-backs fail and Commercial growth reverts to high-single digits
- Falcon / Aspen fail to commercialize; AI narrative de-rates without revenue proof
- Multiple compresses to ~22× on ~$8–9 non-GAAP EPS → ~$180; still a franchise, but de-rated from compounder premium

### Base — $320

Mid-teens subscription holds, Vault CRM completes top-20 conversion, margins stay ~44%+, and the market pays ~30–32× on look-through earnings.

- FY2027 non-GAAP EPS lands near ~$9.21; FY2028 EPS grows mid-teens as CRM and R&D/Quality compound
- Subscription prints in the guided ~15% zone; R&D/Quality stays high-teens; Commercial holds low-double digits+
- Non-GAAP OI margin holds ~44%; buybacks continue against the ~$1.4B authorization
- ~31× on ~$10–11 look-through non-GAAP EPS supports ~$320

### Bull — $420

Vault CRM sweeps remaining top 20, Falcon becomes a real attach engine, and the multiple expands on re-accelerating subscription.

- Top-20 Vault CRM commitments convert and win-backs land; Commercial re-accelerates toward mid-teens
- Falcon / Vault AI print meaningful ARR with top-20 go-lives; Aspen shows early horizontal traction without diluting focus
- Subscription sustains high-teens and non-GAAP margins expand modestly above 45%
- Market restores ~35× on growing earnings → ~$420

---

InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.